Published on
August 3, 2026
- 17:28 GMT
AriBio Completes Treatment Phase of Global Phase 3 POLARIS-AD Trial of AR1001 for Early Alzheimer’s Disease
Pivotal Phase 3 registration trial advances to database lock and analysis; Topline results expected in Q4’26; Results planned for presentation at CTAD 2026 SEONGNAM-SI, SOUTH KOREA, August 3, 2026 /EINPresswire.com/ -- AriBio Co., Ltd., a clinical- …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
